Meeting
2023 ASCO Breakthrough
Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): Updated results from a phase Ib/II study.
Authors
Xiaojia Wang
Department of Oncology, Zhejiang Cancer Hospital, Hangzhou, China
Xiaojia Wang , Keun Seok Lee , Xiaohua Zeng , Tao Sun , Young-Hyuck Im , Huiping Li , Kun Wang , Huiyan Li , Ping Zhou , Yuanyuan Bao , Zefei Jiang
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast Cancer,Central Nervous System Tumors,Developmental Therapeutics,Genitourinary Cancer,Hematologic Malignancies,Thoracic Cancers,Other Malignancies or Topics
Sub Track
Targeted Therapies
Clinical Trial Registration Number
NCT04276493
Citation
JCO Global Oncology 9, 2023 (suppl 1; abstr 1)
DOI
10.1200/GO.2023.9.Supplement_1.1
Abstract #
1
Poster Bd #
A1
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): Updated results from a phase 1b/2 study.
First Author: Xiaojia Wang
Poster
2022 ASCO Annual Meeting
Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line (1L) therapy for patients (pts) with advanced HER2-positive breast cancer: Preliminary results from a phase 1b/2 study.
First Author: Keun-Seok Lee
Poster
2021 ASCO Annual Meeting
Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.
First Author: Keun Wook Lee
Poster
2020 ASCO Virtual Scientific Program
ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.
First Author: Do-Youn Oh